Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 03/11/21
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of CancerBusiness Wire • 01/26/21
Bicycle Therapeutics to Present at the 2020 Piper Sandler Healthcare ConferenceBusiness Wire • 11/24/20
Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.Business Wire • 11/20/20
Bicycle Therapeutics to Present at the Jefferies Virtual London Healthcare ConferenceBusiness Wire • 11/12/20
Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual MeetingBusiness Wire • 11/09/20
Bicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 11/05/20
Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual MeetingBusiness Wire • 10/14/20
Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules CapitalBusiness Wire • 10/01/20
Bicycle Therapeutics to Present Trials in Progress Poster for BT8009 at the ESMO Virtual Congress 2020Business Wire • 09/14/20
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid TumorsBusiness Wire • 09/10/20
Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718Business Wire • 09/02/20
Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular EdemaBusiness Wire • 09/01/20
Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth ConferenceBusiness Wire • 08/05/20
Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 08/05/20
Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory BoardBusiness Wire • 06/23/20
Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting IIBusiness Wire • 06/22/20